Sponsor Pipeline

Immuneering Corporation Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
1
Recruiting
1
Phase 3
4
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-28 NCT07562152
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic…		 Trial sites expanded: 25 -> 30 locations
Active Trials by Phase
Phase 3
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic… Pancreatic Cancer Recruiting
Phase 1/2
NCT05585320 A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors Advanced Solid Tumor Active, Not Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Melanoma (1) Pancreatic Cancer (1)
Get alerts when Immuneering Corporation's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free